Dr Ibrahim Khadra
Reader
Strathclyde Institute of Pharmacy and Biomedical Sciences
Publications
- Structured solubility behaviour in fed simulated intestinal fluids
- Silva Maria Inês, Khadra Ibrahim, Pyper Kate, Halbert Gavin W
- European Journal of Pharmaceutics and Biopharmaceutics Vol 193, pp. 58-73 (2023)
- https://doi.org/10.1016/j.ejpb.2023.10.017
- Characterisation of ciprofloxacin-loaded polymeric fiber mats prepared by meltelectrospinning
- Obeid Mohammad A, Akil Lina, A Aljabali Alaa, Khadra Ibrahim
- Macromolecular Materials and Engineering (2023)
- https://doi.org/10.1002/mame.202300376
- The impact of solvent selection on the characteristics of niosome nanoparticles prepared by microfluidic mixing
- Obeid Mohammad A, Haifawi Saja, Khadra Ibrahim
- International Journal of Pharmaceutics: X Vol 5 (2023)
- https://doi.org/10.1016/j.ijpx.2023.100168
- Study of in vitro poorly soluble drug solubility into fasted state simulated intestinal fluid reflective of in vivo gastrointestinal variability
- McKinnon Zoe, Batchelor Hannah, Khadra Ibrahim, Halbert Gavin
- British Journal of Pharmacy Vol 8 (2023)
- https://doi.org/10.5920/bjpharm.1380
- Excipients impact on fenofibrate equilibrium solubility in fasted and fed simulated intestinal fluids assessed using a design of experiment protocol
- Ainousah Bayan E, Khadra Ibrahim, Halbert Gavin W
- Pharmaceutics Vol 15 (2023)
- https://doi.org/10.3390/pharmaceutics15102484
- Fed intestinal solubility limits and distributions applied to the developability classification system
- Silva Maria Inês, Khadra Ibrahim, Pyper Kate, Halbert Gavin W
- European Journal of Pharmaceutics and Biopharmaceutics Vol 186, pp. 74-84 (2023)
- https://doi.org/10.1016/j.ejpb.2023.03.005
Research Interests
1- Oral Drug Delivery/Formulation
Orodispersible thin films (OTFs) were first established as breath fresheners and have since progressed to the delivery of active pharmaceutical ingredients (APIs). Composed principally of one or more water soluble, film-forming polymers, OTFs dissolve very rapidly in contact with saliva, releasing the active ingredient(s) without the need to chew or drink water. This makes them ideally suited to elderly or paediatric populations, who may have difficulty swallowing other solid oral dosage forms such as tablets or capsules.
This is a growing area with a lot of industrial interest and lack of regulatory information and quick turn over for generic API; therefore the focus will be on the following area:
- Tatse Masking of API
- The use of sweetener and flavour as a taste mask strategy
- Dissolution assays and Biowavier
- Thin film stability following the ICH guidelines
- The use of different film former polymer for different purposes (IR, SR, and wound care application)
2- Oral Biopharmaceutics
As most drugs are taken orally, as tablets or capsules for example. However, designing these pharmaceutical products in such a way that the active ingredient is absorbed at an appropriate rate and extent by the gut is far from easy. Therefore to be able to enhance the understanding of how orally-administered drugs are taken up from the gastrointestinal tract into the body, and apply this knowledge to create new laboratory tests and computer models that will better predict the performance of these drugs in patients.
This is another area of industrial and regulatory interest for which I will follow and continue the research generated and initiated in the oral biopharmaceutical tools project “Orbito” – we will also collaborate with our current industrial partners e.g. GSK, Pfizer, AZ, Novartis and others, and will be linked to colleague in CMAC (Professor Joop Ter Horst, CRUK (Professor Gavin Halbert) and also with the regulatory authorities in UK, Europe and USA.
The focus will be on the following:
- API physicochemical characterization
- Drug solubility in human gastric and intestinal fluids “fed and fasted state” using the DOE approach
- Develop small-scale tests for dissolution, nucleation and supersaturation.
- Develop of predictive tools that the industrial partners can use to predict the behavior of their API.
3- Extrusion, 3D and Chocolate Printing
The applications of three dimensional (3D) printing in the field of pharmaceutical science and medicine are growing rapidly and the technique generates numerous benefits currently and also very promising potential applications in the near future such as drug discovery and delivery and tissue fabrication. 3D printing technology offers many advantages, for example, it permits customization of products and therefore it can be applied on a number of areas, such as drug delivery or tissue engineering.
The work in this area started and project with a leading Pharamceutical Compnay has been initiated which focus on the extrusion of drug loaded filament and the use of 3D printing technology to print a design for female health care.
Also the use of chocolate as drug delivery system for pediatric application is another growing area, the chocolate printer was developed in house and ready to use. This work is coordinated and led by Professor Clive Wilson and myself.
Professional Activities
- University of Strathclyde (Event)
- Chair
- 8/2022
- EDAN Annual Conference
- Speaker
- 2/5/2022
- UNGAP Meeting
- Speaker
- 1/3/2022
- University of Strathclyde (Event)
- Advisor
- 1/2022
- Palestine Syndicate of Pharmacists (External organisation)
- Advisor
- 1/1/2022
- Strathclyde Institute Of Pharmacy And Biomedical Sciences (Organisational unit)
- Member
- 12/2021
Projects
- GiBio Gastrointestinal bioreactor to evaluate ingestible medicines and inform formulation and manufacture (EPSRC Strategic equipment)
- Batchelor, Hannah (Principal Investigator) Florence, Alastair (Co-investigator) Horan, Linda (Co-investigator) Khadra, Ibrahim (Co-investigator) McArthur, Stephen (Co-investigator)
- 01-Jan-2022 - 30-Jan-2025
- DTP 2224 University of Strathclyde | Abu-Rajab Tamimi, Rana
- Khadra, Ibrahim (Principal Investigator) Batchelor, Hannah (Co-investigator) Abu-Rajab Tamimi, Rana (Research Co-investigator)
- 01-Jan-2022 - 01-Jan-2026
- Understanding long-term stability of solid pharmaceutical dosage forms by characterisation
- Markl, Daniel (Principal Investigator) Khadra, Ibrahim (Co-investigator)
- 01-Jan-2021 - 31-Jan-2024
- Industrial Case Account - University of Strathclyde 2020 | Jesney, Hannah
- Markl, Daniel (Principal Investigator) Khadra, Ibrahim (Co-investigator) Jesney, Hannah (Research Co-investigator)
- 01-Jan-2020 - 01-Jan-2024
- Biocompatible silk hydrogels as tunable stem cell constructs for the treatment of stroke. (skype)
- Carswell, Hilary (Principal Investigator) Seib, Philipp (Co-investigator) Khadra, Ibrahim (Research Co-investigator)
- 01-Jan-2020 - 30-Jan-2023
- Erasmus International Credit Mobility, Middle East University and Strathclyde
- Khadra, Ibrahim (Principal Investigator)
- Erasmus International Credit Mobility, Faculty of Pharmacy, Middle East University, Jordan. (Total Funding of £80k)
- 01-Jan-2020 - 01-Jan-2024
Contact
Dr
Ibrahim
Khadra
Reader
Strathclyde Institute of Pharmacy and Biomedical Sciences
Email: ibrahim.khadra@strath.ac.uk
Tel: 548 2654